Biosynex SA (EPA:ALBIO)

Biosynex Statistics

Total Valuation

Biosynex has a market cap or net worth of EUR 19.50 million. The enterprise value is 71.78 million.

Market Cap	19.50M
Enterprise Value	71.78M

Important Dates

The next estimated earnings date is Thursday, April 30, 2026.

Earnings Date	Apr 30, 2026
Ex-Dividend Date	n/a

Share Statistics

Biosynex has 18.75 million shares outstanding. The number of shares has increased by 32.73% in one year.

Current Share Class	18.75M
Shares Outstanding	18.75M
Shares Change (YoY)	+32.73%
Shares Change (QoQ)	+74.10%
Owned by Insiders (%)	5.70%
Owned by Institutions (%)	n/a
Float	8.10M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.20
PB Ratio	0.41
P/TBV Ratio	6.88
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-1.01
EV / Sales	0.73
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-7.07

Financial Position

The company has a current ratio of 0.85, with a Debt / Equity ratio of 1.29.

Current Ratio	0.85
Quick Ratio	0.43
Debt / Equity	1.29
Debt / EBITDA	n/a
Debt / FCF	-6.11
Interest Coverage	-10.29

Financial Efficiency

Return on equity (ROE) is -93.80% and return on invested capital (ROIC) is -42.48%.

Return on Equity (ROE)	-93.80%
Return on Assets (ROA)	-14.87%
Return on Invested Capital (ROIC)	-42.48%
Return on Capital Employed (ROCE)	-55.69%
Weighted Average Cost of Capital (WACC)	5.72%
Revenue Per Employee	215,756
Profits Per Employee	-156,363
Employee Count	476
Asset Turnover	0.55
Inventory Turnover	1.28

Taxes

Income Tax	-3.36M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -25.20% in the last 52 weeks. The beta is 0.52, so Biosynex's price volatility has been lower than the market average.

Beta (5Y)	0.52
52-Week Price Change	-25.20%
50-Day Moving Average	0.61
200-Day Moving Average	0.98
Relative Strength Index (RSI)	66.67
Average Volume (20 Days)	85,884

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Biosynex had revenue of EUR 97.95 million and -70.99 million in losses. Loss per share was -4.82.

Revenue	97.95M
Gross Profit	57.50M
Operating Income	-42.62M
Pretax Income	-74.30M
Net Income	-70.99M
EBITDA	-17.94M
EBIT	-42.62M
Loss Per Share	-4.82

Balance Sheet

The company has 9.76 million in cash and 62.05 million in debt, with a net cash position of -52.28 million or -2.79 per share.

Cash & Cash Equivalents	9.76M
Total Debt	62.05M
Net Cash	-52.28M
Net Cash Per Share	-2.79
Equity (Book Value)	48.05M
Book Value Per Share	2.56
Working Capital	-11.16M

Cash Flow

In the last 12 months, operating cash flow was -5.81 million and capital expenditures -4.35 million, giving a free cash flow of -10.16 million.

Operating Cash Flow	-5.81M
Capital Expenditures	-4.35M
Free Cash Flow	-10.16M
FCF Per Share	-0.54

Margins

Gross margin is 58.71%, with operating and profit margins of -43.51% and -72.47%.

Gross Margin	58.71%
Operating Margin	-43.51%
Pretax Margin	-75.85%
Profit Margin	-72.47%
EBITDA Margin	-18.31%
EBIT Margin	-43.51%
FCF Margin	n/a

Dividends & Yields

Biosynex does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-32.73%
Shareholder Yield	-32.73%
Earnings Yield	-364.08%
FCF Yield	-52.09%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Biosynex has an Altman Z-Score of -0.65 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.65
Piotroski F-Score	5